{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T22:08:07Z","timestamp":1791583687659,"version":"4.3.4"},"reference-count":61,"publisher":"Canadian Science Publishing","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.nrcresearchpress.com\/page\/about\/CorporateTextAndDataMining"}],"content-domain":{"domain":["cdnsciencepub.com"],"crossmark-restriction":false},"short-container-title":["Can. J. Physiol. Pharmacol."],"published-print":{"date-parts":[[2026,1,1]]},"abstract":"<jats:p>Incretin therapies have emerged as key interventions for glycemic control and weight reduction and are now among Canada\u2019s costliest outpatient drug classes. This review synthesizes current clinical and economic evidence on the cost-effectiveness of incretin-based therapies. These include glucagon-like peptide-1 receptor agonists (GLP-1RAs; e.g., semaglutide) and dual agonists (e.g., tirzepatide) targeting both glucose-dependent insulinotropic polypeptide and GLP-1 receptors, in patients with type 2 diabetes mellitus or for weight loss. We review data from clinical trials and recent Canadian and international economic models, identify emerging indications, and discuss limitations in current health-technology assessment frameworks. Implications for Canadian reimbursement are highlighted, with attention to price, patient selection, and outcome considerations.<\/jats:p>","DOI":"10.1139\/cjpp-2025-0248","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T22:00:42Z","timestamp":1776808842000},"page":"1-7","update-policy":"https:\/\/doi.org\/10.1139\/csp-crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Cost-effectiveness of incretin therapies: a Canadian lens on diabetes, obesity, and emerging indications"],"prefix":"10.1139","volume":"104","author":[{"given":"Luke","family":"Awadalla","sequence":"first","affiliation":[{"name":"Western University","place":["London, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siena","family":"Iskander","sequence":"additional","affiliation":[{"name":"Queen\u2019s University","place":["Kingston, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cherry","family":"Chu","sequence":"additional","affiliation":[{"name":"Women's College Hospital Research and Innovation Institute","place":["Toronto, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1911-6129","authenticated-orcid":false,"given":"Mina","family":"Tadrous","sequence":"additional","affiliation":[{"name":"Women's College Hospital Research and Innovation Institute","place":["Toronto, Canada"]},{"name":"University of Toronto","place":["Toronto, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"155","reference":[{"issue":"3","key":"refg1\/ref1","first-page":"24nr03828","volume":"27","author":"Ali M.","year":"2025","journal-title":"Prim Care Companion CNS Disord."},{"key":"refg2\/ref2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12144575"},{"issue":"12","key":"refg3\/ref3","first-page":"6","volume":"20","author":"Anonymous","year":"2024","journal-title":"Gastroenterol. Hepatol. (NY)"},{"key":"refg4\/ref4","volume-title":"What is the BRAVOTM model?","author":"Anonymous"},{"key":"refg5\/ref5","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.24945"},{"key":"refg6\/ref6","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14940"},{"key":"refg7\/ref7","doi-asserted-by":"publisher","DOI":"10.57264\/cer-2023-0178"},{"key":"refg8\/ref8","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph20054637"},{"key":"refg9\/ref9","volume-title":"What is next in the evolution of GLP-1-based therapies for diabetes and obesity?","author":"Brubaker P.","year":"2023"},{"key":"refg10\/ref10","doi-asserted-by":"publisher","DOI":"10.1016\/S1262-3636(08)73398-6"},{"key":"refg11\/ref11","volume-title":"CADTH common drug review: pharmacoeconomic review report for ozempic","author":"CADTH","year":"2019"},{"issue":"10","key":"refg12\/ref12","volume":"2","author":"CADTH","year":"2022","journal-title":"Can. J. Health Technol"},{"key":"refg13\/ref13","unstructured":"Canadian Institute for Health Information. 2023. Canada's public drug program spending reaches $18.4 billion in 2023, medications like Ozempic driving cost.Available at:\u00a0https:\/\/www.cihi.ca\/en\/news\/canadas-public-drug-program-spending-reaches-184-billion-in-2023-medications-like-ozempic-driving [accessed 16 April 2026]."},{"key":"refg14\/ref14","volume-title":"Canadian Centre on Substance Use and Addiction","author":"Canadian Institute for Substance Use Research (CISUR)","year":"2020"},{"key":"refg15\/ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jagp.2023.08.010"},{"key":"refg16\/ref16","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.27258"},{"key":"refg17\/ref17","doi-asserted-by":"publisher","DOI":"10.1002\/hec.3086"},{"key":"refg18\/ref18","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2024.1380690"},{"key":"refg19\/ref19","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2020.20272"},{"key":"refg20\/ref20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107519"},{"key":"refg21\/ref21","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31149-3"},{"key":"refg22\/ref22","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvae163.044"},{"key":"refg23\/ref23","doi-asserted-by":"publisher","DOI":"10.1007\/s40266-021-00853-7"},{"key":"refg24\/ref24","unstructured":"Government of Canada, 2025. Diabetes: Overview. Available from https:\/\/www.canada.ca\/en\/public-health\/services\/diseases\/diabetes.html#a2 [accessed 16 April 2026]."},{"key":"refg25\/ref25","unstructured":"Government of Ontario. 2024. Executive officer notice: update to ozempic listing\u2013change in status to limited use benefit. Ministry of Health, Health Programs and Delivery Division\u00a0. Available from https:\/\/www.ontario.ca\/files\/2024-01\/moh-executive-officer-notice-en-2024-01-26.pdf."},{"key":"refg26\/ref26","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12081630"},{"key":"refg27\/ref27","doi-asserted-by":"publisher","DOI":"10.1002\/oby.24310"},{"key":"refg28\/ref28","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2025.0905"},{"issue":"7","key":"refg29\/ref29","volume":"5","author":"Jamieson P.B.","year":"2025","journal-title":"Can. J. Health Technol"},{"key":"refg30\/ref30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206038"},{"key":"refg31\/ref31","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2307563"},{"key":"refg32\/ref32","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2025.31.5.441"},{"key":"refg33\/ref33","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2025.1513641"},{"key":"refg34\/ref34","doi-asserted-by":"publisher","DOI":"10.2337\/dc24-2241"},{"key":"refg35\/ref35","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2401943"},{"key":"refg36\/ref36","doi-asserted-by":"publisher","DOI":"10.1038\/mp.2017.187"},{"key":"refg37\/ref37","doi-asserted-by":"publisher","DOI":"10.9778\/cmajo.20210205"},{"key":"refg38\/ref38","volume-title":"General health","author":"Maple","year":"2024"},{"key":"refg39\/ref39","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607141"},{"key":"refg40\/ref40","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2024.112424"},{"key":"refg41\/ref41","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2025.2459529"},{"key":"refg42\/ref42","author":"Modarressi T.","year":"2024","journal-title":"Am. Coll. Cardiol"},{"key":"refg43\/ref43","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-800101-1.00002-8"},{"key":"refg44\/ref44","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.117.028136"},{"key":"refg45\/ref45","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1405158"},{"key":"refg46\/ref46","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2505928"},{"key":"refg47\/ref47","doi-asserted-by":"publisher","DOI":"10.1787\/7a7afb35-en"},{"key":"refg48\/ref48","doi-asserted-by":"publisher","DOI":"10.1038\/s41366-024-01467-w"},{"key":"refg49\/ref49","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m4573"},{"key":"refg50\/ref50","unstructured":"Pederson S. 2025. Zepbound (Mounjaro\/Tirzepatide) for weight management approved in Canada. 2025. Available from https:\/\/drsue.ca\/2025\/05\/zepbound-mounjaro-tirzepatide-approved-canada\/ [accessed 16 April 2026]."},{"key":"refg51\/ref51","volume-title":"Eligibility requirements, annual maximum as leading cost control methods international foundation of employee benefit plans blog","author":"Plier R.","year":"2025"},{"key":"refg52\/ref52","volume-title":"Regulatory Decision Summary for Wegovy (Government of Canada)","year":"2021"},{"key":"refg53\/ref53","doi-asserted-by":"publisher","DOI":"10.1016\/j.cjca.2024.09.025"},{"key":"refg54\/ref54","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-025-03002-1"},{"key":"refg55\/ref55","doi-asserted-by":"publisher","DOI":"10.1186\/s13098-024-01338-4"},{"key":"refg56\/ref56","doi-asserted-by":"publisher","DOI":"10.1007\/s40258-022-00726-z"},{"key":"refg57\/ref57","doi-asserted-by":"publisher","DOI":"10.51731\/cjht.2024.1049"},{"key":"refg58\/ref58","doi-asserted-by":"publisher","DOI":"10.1111\/dom.16466"},{"key":"refg59\/ref59","doi-asserted-by":"publisher","DOI":"10.2147\/CEOR.S24192"},{"key":"refg60\/ref60","volume-title":"Clinical pearls: new pharmacotherapy in the treatment of type 2 diabetes\u2014tirzepatide","author":"Wingate H.","year":"2023"},{"key":"refg61\/ref61","doi-asserted-by":"publisher","DOI":"10.1186\/s12902-023-01500-5"}],"container-title":["Canadian Journal of Physiology and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/cdnsciencepub.com\/doi\/full-xml\/10.1139\/cjpp-2025-0248","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/cdnsciencepub.com\/doi\/pdf\/10.1139\/cjpp-2025-0248","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T16:52:53Z","timestamp":1779209573000},"score":1,"resource":{"primary":{"URL":"https:\/\/cdnsciencepub.com\/doi\/10.1139\/cjpp-2025-0248"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,1]]},"references-count":61,"alternative-id":["10.1139\/cjpp-2025-0248"],"URL":"https:\/\/doi.org\/10.1139\/cjpp-2025-0248","relation":{},"ISSN":["0008-4212","1205-7541"],"issn-type":[{"value":"0008-4212","type":"print"},{"value":"1205-7541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,1]]},"assertion":[{"value":"2026-05-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}